行情

XENT

XENT

Intersect ENT
NASDAQ

实时行情|Nasdaq Last Sale

26.76
-0.81
-2.94%
盘后: 26.76 0 0.00% 16:49 02/21 EST
开盘
27.70
昨收
27.57
最高
27.93
最低
26.54
成交量
72.25万
成交额
--
52周最高
35.87
52周最低
14.62
市值
8.43亿
市盈率(TTM)
-20.8281
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测XENT价格均价为27.57,最高价位31.00,最低价为21.00。

EPS

XENT 新闻

更多
  • Earnings Preview: Intersect ENT (XENT) Q4 Earnings Expected to Decline
  • Zacks · 5天前
  • Intersect ENT to Present at the 9th Annual SVB Leerink Global Healthcare Conference
  • Business Wire · 02/05 21:05
  • Intersect ENT to Report Fourth Quarter and Year 2019 Financial Results
  • Business Wire · 02/05 21:05
  • New Product Suite Boosts Intersect ENT Despite Cost Concerns
  • Zacks · 01/23 15:48

所属板块

医疗设备、用品及经销
-0.81%
医疗设备和用品
-0.65%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

XENT 简况

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.
展开

微牛提供Intersect ENT Inc(NASDAQ-XENT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的XENT股票新闻,以帮助您做出投资决策。